Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 59

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 59
---
 short lasting.

 25 

We
believe Spryng® is an optimal solution to safely improve joint function in animals for several reasons:

    ●
    Spryng® addresses the
    underlying problems which relate to deterioration of cartilage causing bones to contact each other and a lack of synovial fluid.
    Spryng® provides a biocompatible lubricious cushion to the joint, which establishes a barrier between the bones, thereby protecting
    the remaining cartilage and bone.

    ●
    Spryng® is easily administered
    with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.

    ●
    Case studies indicate many
    dogs and horses have long-lasting multi-month improvement in lameness after having been treated with Spryng®.

    ●
    After receiving a Spryng®
    injection, many canines are able to discontinue the use of NSAID’s, eliminating the risk of negative side effects.

    ●
    Spryng® is an effective
    and economical solution for treating osteoarthritis. A single injection of Spryng® is approximately $600 to $900 per joint and
    typically lasts for at least 12 months.

Historically,
drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary
practices are being eroded because online, big-box, and traditional pharmacies have recently started filling veterinary prescriptions.
Veterinary practices are looking for ways to replace lost prescription revenues with safe and effective products. Spryng® is a veterinarian-administered
medical device that should expand practice revenues and margins. We believe that the increased revenues and margins provided by Spryng®
will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial
joint issues.

We
commenced sales of Spryng® in the second quarter of fiscal 2022 and plan to increase our commercialization efforts of Spryng®
in the United States through our distribution relationship with MWI Veterinary Supply Co. (“Distributor” or “MWI”), Vedco, Inc.
and the use of sales reps, clinical studies, and market awareness to educate and inform key opinion leaders on the benefits of Spryng®.

VetStem,
Inc.

On
February 14, 2025, the “Company” and VetStem, Inc.